Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:57:05.865Z.
Calculation as of: 2026-10-06T15:57:05.865Z.
Quote observation: 2026-10-06T15:54:55.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 820e6844a86ebcce87b4cbc727545bf8fd5f2e7882f78b89935f6b0fc3bd738c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Larimar Therapeutics, Inc.
Market Cap
$296.13M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$290.50M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$288.68M
Price/OCF Ratio
N/A
TTM Avg
4132.33
3Y Avg
4132.33
5Y Avg
4132.33
Market Cap
$310.88M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$285.37M
Price/OCF Ratio
N/A
TTM Avg
2.51
3Y Avg
2.51
5Y Avg
2.51
Market Cap
$284.21M
Price/OCF Ratio
N/A
TTM Avg
55.15
3Y Avg
55.15
5Y Avg
55.15
Market Cap
$280.91M
Price/OCF Ratio
N/A
TTM Avg
108.55
3Y Avg
108.55
5Y Avg
108.55
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Larimar Therapeutics, Inc. (LRMR) | $296.13M | N/A | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $301.43M | N/A | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $289.76M | N/A | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $290.50M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.68M | N/A | 4132.33 | 4132.33 | 4132.33 |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $310.88M | N/A | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $285.37M | N/A | 2.51 | 2.51 | 2.51 |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $284.21M | N/A | 55.15 | 55.15 | 55.15 |
| Aurora Cannabis Inc. (ACB)vs › | $280.91M | N/A | 108.55 | 108.55 | 108.55 |
| Fate Therapeutics, Inc. (FATE)vs › | $277.99M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
